When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CASI - CASI Pharma's CD19 CAR-T clinical trial applications OK'd in China
CASI Pharmaceuticals Inc.
The China National Medical Product Administration (NMPA) has approved CASI Pharmaceuticals' (NASDAQ:CASI) clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL) submitted by its partner Juventas Cell Therapy Ltd.
More news on: CASI Pharmaceuticals, Inc., Healthcare stocks news,